Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

Stifel analysts increased the price target for Confluent Inc (NASDAQ:CFLT), a data streaming platform, from $37.00 to $40.00, ...

Onsemi (NASDAQ:ON – Get Free Report) had its price objective reduced by research analysts at Stifel Nicolaus from $60.00 to $52.00 in a research note issued on Tuesday,Benzinga reports. The firm ...

Stifel Financial is a top pick for long-term growth with solid Q424 results, a 10% dividend hike & solid wealth management ...

Stifel raised the firm’s price target on Confluent (CFLT) to $40 from $37 and keeps a Buy rating on the shares following what the firm calls “a ...

SPS Commerce (NASDAQ:SPSC – Get Free Report) had its price target decreased by analysts at Stifel Nicolaus from $225.00 to $200.00 in a report released on Tuesday,Benzinga reports. The brokerage ...

MoneyLion operates a “content-as-a-service platform” called mFeed, and Stifel Discover is expected to deliver personalized ...

GATX Corporation (NYSE: GATX) announced the cancellation of its presentation and webcast at the Stifel 2025 Transportation & ...

Over the past five years, Stifel has hired 450 advisors, with a cumulative trailing 12-month production of more than $350 million, according to CFO Marischen. That has driven the wealth division’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stifel Financial Corp. provides securities brokerage, investment banking, trading, investment advisory and related financial services. It operates through the following segments: Global Wealth ...